Incidence of dementia · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · older people with age‐related memory loss
NSAIDs (celecoxib) may leads to higher adverse events – gastrointestinal compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive decline · older people with age‐related memory loss
1 finding from 1 review
Activities of daily living · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
2 studies
GRADE not reported
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3 (NSAIDs vs placebo), Cancer development: SoF cell 'Not measured'. Effects text: cancer development was among outcomes in Papadimitrakopoulou 2008 (celecoxib) but did not occur in either arm, probably because of…
1 study
GRADE not reported
Quality of life · patients with osteoarthritis
1 finding from 1 review
Number withdrawn due to adverse events · patients with osteoarthritis
Celecoxib showed no clear difference in number withdrawn due to adverse events compared with tNSAIDs (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with tNSAIDs (very low certainty).
1 finding from 1 review
Number experiencing gastro‐intestinal events (perforation, ulcer, bleeds) · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing gastro‐intestinal events (perforation, ulcer,… compared with tNSAIDs (very low certainty).
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing cardiovascular events (myocardial infarction,… compared with tNSAIDs (very low certainty).
1 finding from 1 review
Pain · patients with osteoarthritis
1 finding from 1 review
Physical function · patients with osteoarthritis
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in cardiovascular events (myocardial infarction, stroke) compared with traditional NSAIDs (low certainty).
1 finding from 1 review
Incidence of gastroduodenal ulcers ≥ 3 mm · patients with rheumatoid arthritis
Celecoxib probably leads to lower incidence of gastroduodenal ulcers ≥ 3 mm compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review